Smokers trying to quit in the future could do it with the help of cannabis based medicines, according to research from The University of Nottingham.
Teams of pharmacologists, studying the cannabis-like compounds which exist naturally in our bodies (endocannabinoids), are exploring the potential for medical treatment. This includes treating conditions as diverse as obesity, diabetes, depression and addiction to substances like nicotine.
Scientists have known about endocannabinoids since the mid-1990s. This led to an explosion in the number of researchers looking into the future medical uses of cannabinoids and cannabis compounds.
Dr Steve Alexander, Associate Professor in the School of Biomedical Sciences, focused on a number of these projects in editing the first themed podcast for the British Journal of Pharmacology.
Dr Alexander said: “It is clear that there is very realistic potential for cannabinoids as medicines. Scientists are looking at a range of possible applications.”
One of these researchers is Professor David Kendall, a cellular pharmacologist at the University: “The brain is full of cannabinoid receptors. And so, not surprisingly with diseases like depression and anxiety, there’s a great deal of interest in exploiting these receptors and in doing so, developing anti-depressant compounds.”
Addiction is a real target — researchers like Professor Kendall believe the endocannabinoids could be a crucial link to addictive behaviour: “We know that the endocannabinoid system is intimately involved in reward pathways and drug seeking behaviour. So this tends to indicate that that if the link involving endocannabinoids and the reward pathway, using inhibitors, can be interrupted, it could turn down the drive to seek addictive agents like nicotine.”
Because cannabinoids have also been shown to bring down blood pressure, it is hoped that related compounds can be used in patients with conditions like hypertension.
Dr Michael Randall, a cardiovascular pharmacologist at the University has looked at how endocannabinoids cause blood vessels to relax. “This could have many implications,” Dr Randall said. “The endocannabinoids appear to lower blood pressure under certain conditions; states of shock for example. If the endocannabinoids are of physiological importance, this could have real therapeutic possibilities.”
“In terms of getting better medicines the endocannabinoid system has a lot to offer,” said Dr Alexander. “The range of cannabis-related medicines is currently limited, but by increasing our knowledge in this area we can increase our stock.”
Source: University of Nottingham
Related stories:
Researchers look at cannabinoids, genes, medicines and brain scans to find better anxiety treatments
Right now, about half of all people who take medicine for an anxiety disorder don’t get much help from it. And doctors have no definitive way to predict who will, and who won’t, benefit from each anti-anxiety prescription they write.
Team announces 'predictor' for pregnant women who may have miscarriages
A medical team from the University of Leicester has been able to establish for the first time a predictor for pregnant women who may have miscarriages and those who won’t. Their research is published in the highly prestigious
Journal of the American Medical Association.
A mechanism for the development of obesity-associated conditions
Substances known as endocannabinoids have been implicated in the development of many effects of a high-fat diet, including risk factors for type 2 diabetes. New data have now indicated that these effects of endocannabinoids occur via activation of the protein CB1 in the liver and not the brain. Therefore, targeting liver CB1 might provide an effective way to treat obesity-related medical conditions without the side effects of targeting CB1 in the brain, anxiety and depression.
Weeding out the highs of medical marijuana
Research exploring new ways of exploiting the full medicinal uses of cannabis while avoiding unwanted side-effects will be presented to pharmacologists today (Tuesday, 15 July) by leading scientists attending the Federation of European Pharmacological Societies Congress, EPHAR 2008.
The body's own 'marijuana' is good for the skin
Scientists from Hungary, Germany and the U.K. have discovered that our own body not only makes chemical compounds similar to the active ingredient in marijuana (THC), but these play an important part in maintaining healthy skin. This finding on "endocannabinoids" just published online in, and scheduled for the October 2008 print issue of,
The FASEB Journal could lead to new drugs that treat skin conditions ranging from acne to dry skin, and even skin-related tumors.
Salutary pizza spice
Oregano doesn´t only give a Pizza its typical taste. Researchers at Bonn University and the ETH Zürich have discovered that this spice also contains a substance which, amongst other qualities, appears to help cure inflammations. The researchers administered its active ingredient – known as beta-caryophyllin (E-BCP) - to mice with inflamed paws. In seven out of ten cases there was a subsequent improvement in the symptoms. E-BCP might possibly be of use against disorders such as osteoporosis and arteriosclerosis. The study has appeared on Monday, 23rd June in the
Proceedings of the National Academy of Sciences (PNAS).
New brain cells implicated in machinery of cannabinoid signaling
The brain cells called astrocytes, and not just neurons, are sensitive to the substances called cannabinoids—the active chemicals in marijuana.
Cannabinoid-blocking weight-loss drug might fight alcoholic fatty liver
The cannabinoid receptors best known for delivering the psychological effects of marijuana also explain the connection between chronic alcohol use and a buildup of fat in the liver, according to a report in the March issue of
Cell Metabolism, a publication of Cell Press. Alcoholic fatty liver can progress to more serious disease, and alcoholism is a leading cause of liver disease in Western societies.